Skip to content

Umbilical Cord Blood Therapy for Children With Global Developmental Delay

Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Children With Global Developmental Delay

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01601158
Enrollment
10
Registered
2012-05-17
Start date
2012-05-31
Completion date
2013-08-31
Last updated
2014-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Global Developmental Delay

Keywords

Global developmental delay, Umbilical cord blood, Rehabilitation

Brief summary

This open-label study aims to evaluate the safety and efficacy of umbilical cord blood therapy for children with global developmental delay.

Detailed description

Global developmental delay (GDD) is a subset of developmental disabilities defined as significant delay in two or more of the following developmental domains: gross/fine motor, speech/language, cognition, social/personal, and activities of daily living. Umbilical cord blood has been used for inherited metabolic diseases that feature global developmental delay and many experimental animal studies have revealed umbilical cord blood is useful to repair neurological impairments in brain.

Interventions

The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.

All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.

Sponsors

MinYoung Kim, M.D.
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Months to 15 Years
Healthy volunteers
No

Inclusion criteria

* Global developmental delay * Willing to comply with all study procedure

Exclusion criteria

* Medical instability including pneumonia or renal function at enrollment * Poor cooperation of guardian,including inactive attitude for rehabilitation and visits for follow-up * Uncontrolled persistent epilepsy * Not eligible according to the principal investigator

Design outcomes

Primary

MeasureTime frameDescription
Changes in CognitionBaseline - 6 months - 12 monthsKorean Wechsler Preschool and Primay Scale of Intelligence (K-WPPSI) (Higher value means better cognitive function (K-WPPSI: below 70 - worst, over 130 - best). The investigators will report K-WPPSI at each assessment time points.
Changes in Cognitive Neurodevelopmental OutcomeBaseline - 1 month - 3 months - 6 months - 12 monthsKorean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scales (Higher value means better cognitive function, K-BSID-II mental scale raw score: 0 - worst, 178 - best). The investigators will report K-BSID-II Mental Scale raw scores at each assessment time points.

Secondary

MeasureTime frameDescription
Changes in Motor Neurodevelopmental OutcomeBaseline - 1 month - 3 months - 6 months - 12 monthsKorean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scales (higher value means better motor function: 0 - worst, 111 - best). The investigators will report K-BSID-II Motor Scale raw scores at each assessment time points.
Changes in Functional Independence in Daily ActivitiesBaseline - 1 month - 3 months - 6 months - 12 monthsWeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher scores mean more independent performance in daily activities. The investigators will report total WeeFIM scores measured at each assessment time points.
Changes in Visual Perception TestBaseline - 1 month - 3 months - 6 months - 12 monthsWe will evaluate visual perception function with one of three measures: DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). All can be scored as percentile rank from 0 to 100. Higher values mean better visual perception ability
Changes in Motor PerformanceBaseline - 1 month - 3 months - 6 months - 12 monthsGMPM (Gross Motor Performance Measure) as a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0\ 100, Higher value means better motor quality). The investigators will report GMPM scores at each assessment time points.
Changes in Functional Performance in Daily ActivitiesBaseline - 1 month - 3 months - 6 months - 12 monthsPediatric Evaluation of Disability Inventory (PEDI) for assessing functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). We will report 2 scales and 3 domains of each scale: a Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) which are divided respectively into 3 domains: self care, mobility, and social function. Categories of outcome table will be each domain scores measured at each assessment time point.
Changes in Language EvaluationBaseline - 6 months - 12 monthsSequenced Language Scale for Infant (SELSI), Preschool Receptive-Expressive Language Scale (PRES) or Korean Western Aphasia Battery (K-WAB) will be used depending on age and function.
Changes in Muscle StrengthBaseline - 1 month - 3 months - 6 months - 12 monthsSummation of MMT (manual muscle strength test score): summated scores of the manual muscle strength test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 \ 160) Higher scores mean better muscle strength. Categories of outcome table will be summation of MMT scores measured at each assessment time point.
Changes in Standardized Gross Motor FunctionBaseline - 1 month - 3 months - 6 months - 12 monthsGMFM (Gross Motor Function Measure) as a standardized measurement tool for assessing Gross Motor Function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0\ 100 , Higher value means better gross motor function). The investigators will report GMFM scores at each assessment time points.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026